

Table S1. Chemotherapy regimens.

Abbreviation	Chemotherapy Regimen	Dose	Days
ACBVP	Doxorubicin	75 mg/m ²	d1
	Cyclophosphamide	1200 mg/m ²	d1
	Vindesine	2 mg/ m ² /d	d1-d5
	Bleomycin	10 mg/m ² /d	d1-d5
	Prednisone	60 mg/m ² /d	d1d5
BEAM	Carmustine	300 mg/m ²	d1
	Cytarabine	200 à 400 mg/m ² /d	d2d5
	Etoposide	200 à 400 mg/m ² /d	d2d5
	Melphalan	140 mg/m ²	d6
CHOP	Doxorubicin	50 mg/m ²	d1
	Cyclophosphamide	750 mg/m ²	d1
	Vincristine	1,4 mg/m ²	d1
	Prednisone	40 mg/m ²	d1d5
COPADEM	Adriamycin	60 mg/m ²	d2
	Methotrexate	3 g/m ²	d1
	Vincristine	1,4 mg/m ²	d1
	Cyclophosphamide	500 mg/m ²	d2d4
	Dexamethasone	40 mg	d1d4
DHAP	Cisplatin	100 mg/m ²	d1
	Cytarabine	2 g/m ² x 2	d2
	Dexamethasone	40 mg/j	d1d4
ESAP	Cisplatin	25 mg/m ²	d1d4
	Etoposide	40 mg/m ² /d	d1d4
	Cytarabine	2 g/m ² /d	d5
	Methylprednisone	500 mg/d	d1d5
MBACOD	Methotrexate	3 g/m ²	d8
	Bleomycin	10 mg/m ²	d1
	Cyclophosphamide	600 mg/m ²	d1
	Doxorubicin	45 mg/m ²	d1
	Vincristine	1 mg/m ²	d1
	Dexamethasone	6 mg/m ²	d1d5

Table S2. Characteristics of patients who received radiotherapy or not.

Characteristic	Whole Cohort (n=93)	No Radiotherapy (n=53)	Radiotherapy (n=40)
Age	57 (48 - 68)	58 (48 - 69)	57 (48 - 75)
Age > 60 years	42 (45%)	25 (47%)	17 (43%)
Gender (M/F)	52/41	27/26	25/15
ECOG > 1	46 (50%)	28 (53%)	18 (45%)
High LDH serum levels	71 (76%)	43 (81%)	28 (70%)
Stage III/IV	80 (86%)	48 (91%)	32 (80%)
aaIPI			
0 - 1	19 (20%)	7 (13%)	12 (30%)
2 - 3	74 (80%)	46 (87%)	28 (70%)
CNS_IPI			
0 - 1	13 (14%)	4 (7%)	9 (23%)
2 - 3	33 (35%)	21 (40%)	12 (30%)
≥ 4	47 (51%)	28 (53%)	19 (47%)
Sites of Skeletal Involvement			
Localized PBL	13 (14%)	5 (9%)	8 (20%)
Multifocal PBL	17 (18%)	9 (17%)	8 (20%)
Secondary Bone Lymphoma	63 (68%)	39 (74%)	24 (60%)
Sites of Skeletal Involvement			
Axial	84 (90%)	51 (96%)	33 (83%)
Skull	7 (8%)	7 (13%)	0
Vertebral	58 (62%)	33 (62%)	25 (63%)
Rib Cage	23 (25%)	16 (30%)	7 (18%)
Pelvis	42 (45%)	27 (51%)	15 (38%)
Distal	36 (39%)	20 (38%)	16 (40%)
Lower Limb	23 (25%)	12 (23%)	11 (28%)
Upper Limb	21 (23%)	12 (23%)	9 (23%)
Epidural Involvement	33 (36%)	16 (30%)	17 (43%)
Bone Marrow Involvement	36 (39%)	22 (42%)	14 (35%)
Prior Low-Grade Lymphoma	14 (15%)	9 (17%)	5 (13%)
Treatment			
Initial Chemotherapy Regimen			
CHOP	79 (85%)	50 (94%)	29 (73%)
MBACOD	12 (13%)	2 (4%)	10 (25%)
Other	2 (2%)	1 (2%)	1 (3%)
High-Dose Methotrexate	50 (54%)	24 (45%)	26 (65%)
Platinum-based Consolidation	21 (23%)	9 (17%)	12 (30%)
High-Dose Cytarabine Consolidation	37 (40%)	17 (32%)	20 (50%)
Intra-Thecal Therapy	39 (42%)	25 (47%)	14 (35%)
Autologous SCT	39 (42%)	21 (40%)	18 (45%)

aaIPI, age-adjusted International Prognostic Index; CNS-IPI, Central Nervous System-IPI; ECOG, Eastern Cooperative Oncology Group; LDH: Lactate DeHydrogenase; PBL, Primary Bone Lymphoma ; SCT, Stem Cell Transplantation.

Table S3. Characteristics of the whole cohort and of patients who received autologous stem cell transplantation or not.

Characteristic	Landmark cohort (n=84)	No ASCT (n=46)	ASCT (n=38)
Age	57 (46 - 65)	63 (50 - 72)	51 (43 - 57)
Age > 60 years	34 (41%)	29 (63%)	5 (13%)
Gender (M/F)	48/38	24/22	24/14
ECOG > 1	37 (44%)	19 (41%)	18 (47%)
High LDH serum levels	62 (74%)	33 (72%)	29 (76%)
Stage III/IV	72 (86%)	35 (76%)	37 (97%)
aaIPI			
0 - 1	19 (23%)	14 (30%)	5 (13%)
2 - 3	65 (77%)	32 (70%)	33 (87%)
Type of Lymphoma			
Localized PBL	12 (14%)	11 (24%)	1 (3%)
Multifocal PBL	17 (20%)	8 (17%)	9 (24%)
Secondary Bone Lymphoma	55 (66%)	27 (59%)	28 (74%)
Sites of Skeletal Involvement			
Axial	75 (89%)	38 (83%)	37 (97%)
Skull	6 (7%)	2 (4%)	4 (11%)
Vertebral	51 (61%)	24 (52%)	27 (71%)
Rib Cage	21 (25%)	10 (22%)	11 (29%)
Pelvis	39 (46%)	19 (41%)	20 (53%)
Distal	33 (39%)	20 (44%)	13 (34%)
Lower Limb	20 (24%)	10 (22%)	10 (26%)
Upper Limb	20 (24%)	14 (30%)	6 (16%)
Epidural Involvement	31 (37%)	12 (26%)	19 (50%)
Bone Marrow Involvement	32 (38%)	12 (26%)	20 (53%)
Prior Low-Grade Lymphoma	13 (16%)	2 (4%)	11 (29%)
Treatment			
Initial Chemotherapy Regimen			
CHOP	70 (83%)	41 (89%)	29 (76%)
MBACOD	12 (14%)	4 (9%)	8 (21%)
Other	2 (2%)	1 (2%)	1 (3%)
High-Dose Methotrexate	50 (60%)	17 (37%)	33 (87%)
Platinum-based Consolidation	19 (23%)	5 (11%)	14 (37%)
High-Dose Cytarabine Consolidation	35 (42%)	8 (17%)	27 (71%)
Intra-Thecal Therapy	37 (44%)	18 (39%)	19 (50%)
Radiotherapy	39 (46%)	21 (46%)	18 (47%)

aaIPI, age-adjusted International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; LDH: Lactate DeHydrogenase; PBL, Primary Bone Lymphoma ; SCT, Stem Cell Transplantation.

Fig S1. Progression-free survival (PFS), in patients < 60 years (A) and > 60 years (B), and overall survival (OS), in patients < 60 years (C) and > 60 years (D), treated with or without HD-MTX.




Fig S2. Progression-free survival (PFS), in patients with a low or intermediate CNS-IPI (A) and a high CNS-IPI (B), and overall survival (OS), in patients with a low or intermediate CNS-IPI (C) and a high CNS-IPI (D), treated with or without HD-MTX.




Fig S3. Progression-free survival (PFS) (A) and overall survival (OS) (B) of patients with secondary bone lymphoma treated with or without HD-MTX.

